72 related articles for article (PubMed ID: 20838214)
1. Visceral and subcutaneous fat in patients treated with olanzapine: a case series.
Gilles M; Hentschel F; Paslakis G; Glahn V; Lederbogen F; Deuschle M
Clin Neuropharmacol; 2010; 33(5):248-9. PubMed ID: 20838214
[TBL] [Abstract][Full Text] [Related]
2. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Raskind MA; Burke BL; Crites NJ; Tapp AM; Rasmussen DD
Neuropsychopharmacology; 2007 Feb; 32(2):284-8. PubMed ID: 16710316
[TBL] [Abstract][Full Text] [Related]
4. A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls.
Joseph AM; Venkatasubramanian G; Sharma PS
East Asian Arch Psychiatry; 2011 Mar; 21(1):10-6. PubMed ID: 21837851
[TBL] [Abstract][Full Text] [Related]
5. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
Narula PK; Rehan HS; Unni KE; Gupta N
Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
[TBL] [Abstract][Full Text] [Related]
6. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
7. Body-mass index, abdominal adiposity, and cardiovascular risk.
Gonçalves FB; Koek M; Verhagen HJ; Niessen WJ; Poldermans D
Lancet; 2011 Jul; 378(9787):227; author reply 228. PubMed ID: 21763933
[No Abstract] [Full Text] [Related]
8. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine increases plasma ghrelin level in patients with schizophrenia.
Murashita M; Kusumi I; Inoue T; Takahashi Y; Hosoda H; Kangawa K; Koyama T
Psychoneuroendocrinology; 2005 Jan; 30(1):106-10. PubMed ID: 15358448
[TBL] [Abstract][Full Text] [Related]
10. Association of olanzapine-induced weight gain with an increase in body fat.
Eder U; Mangweth B; Ebenbichler C; Weiss E; Hofer A; Hummer M; Kemmler G; Lechleitner M; Fleischhacker WW
Am J Psychiatry; 2001 Oct; 158(10):1719-22. PubMed ID: 11579009
[TBL] [Abstract][Full Text] [Related]
11. Dietary calcium intake is associated with less gain in intra-abdominal adipose tissue over 1 year.
Bush NC; Alvarez JA; Choquette SS; Hunter GR; Oster RA; Darnell BE; Gower BA
Obesity (Silver Spring); 2010 Nov; 18(11):2101-4. PubMed ID: 20203630
[TBL] [Abstract][Full Text] [Related]
12. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.
Park YM; Cho JH; Kang SG; Choi JE; Lee SH; Kim L; Lee HJ
J Clin Pharm Ther; 2008 Feb; 33(1):55-60. PubMed ID: 18211617
[TBL] [Abstract][Full Text] [Related]
13. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
[TBL] [Abstract][Full Text] [Related]
14. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
Cooper GD; Harrold JA; Halford JC; Goudie AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
[TBL] [Abstract][Full Text] [Related]
15. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
Coccurello R; Caprioli A; Ghirardi O; Conti R; Ciani B; Daniele S; Bartolomucci A; Moles A
Psychopharmacology (Berl); 2006 Jul; 186(4):561-71. PubMed ID: 16758241
[TBL] [Abstract][Full Text] [Related]
17. Lower Subcutaneous or Visceral Adiposity Assessed by Abdominal Computed Tomography Could Predict Adverse Outcome in Patients With Crohn's Disease.
Thiberge C; Charpentier C; Gillibert A; Modzelewski R; Dacher JN; Savoye G; Savoye-Collet C
J Crohns Colitis; 2018 Nov; 12(12):1429-1437. PubMed ID: 30260374
[TBL] [Abstract][Full Text] [Related]
18. Investigation of relation between visceral and subcutaneous abdominal fat volumes and calcified aortic plaques via multislice computed tomography.
Efe D; Aygün F; Acar T; Yildiz M; Gemici K
Vascular; 2015 Aug; 23(4):396-402. PubMed ID: 25245049
[TBL] [Abstract][Full Text] [Related]
19. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
20. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
